Pfizer Operating Margin vs. Operating Margin
Pfizer Inc is regarded second in operating margin category among related companies. It is rated below average in return on asset category among related companies reporting about 0.18 of Return On Asset per Operating Margin. The ratio of Operating Margin to Return On Asset for Pfizer Inc is roughly 5.68Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or pay out its debt which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against firm's competitors.Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Pfizer is rated below average in return on asset category among related companies.
Pfizer is considered to be number one stock in operating margin category among related companies.
Other Pfizer Fundamental Comparison
Use alpha and beta coefficients to find investment opportunities after accounting for the riskFind Alpha
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals, sectors and familiesResearch Equities
Find insiders across different sectors to evaluate their impact on performance and growth of their entitiesResearch Insiders